Nikolinka Koleva

Nikolinka Koleva

Auto-generated profile, based on publicly available information

Nikolinka Koleva

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Medical University, 5800 Pleven, Bulgaria

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Boris DinkovBoris Dinkov
Boris Dinkov
NKNikolinka Koleva
Nikolinka Koleva
GSGalya Stavreva
Galya Stavreva
Oral absorption remains challenging for peptides, proteins, and other drug substances with limited stability or permeability. Sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC), also known as salcaprozate sodium, is an oral permeation enhancer used in approved drug products. This review summarizes the physicochemical properties and mechanisms of action of SNAC and evaluates its clinical and emerging preclinical applications. A structured literature search was conducted in PubMed and Scopus, supplemented as needed with ClinicalTrials.gov and regulatory documents. The search covered 2015–2026, with earlier key publications included where necessary for historical context. After screening, 71 sources were included in the narrative synthesis. The review examines the proposed mechanisms of SNAC-mediated permeation enhancement, including local pH modulation, membrane-mediated effects, peptide self-association, and context-dependent effects on epithelial permeability. Clinical evidence is summarized for oral semaglutide, cyanocobalamin, unfractionated heparin, ibandronate, and investigational peptide products. Emerging applications beyond metabolic diseases are discussed together with formulation strategies and safety considerations. Recent preclinical findings suggesting changes in gut microbiota and inflammatory markers are critically evaluated in the context of the available clinical safety experience, while their relevance to humans remains unconfirmed. Overall, SNAC reliably enhances permeation in vitro and in vivo, yet the resulting oral bioavailability remains low and variable and is strongly dependent on payload, formulation, and gastrointestinal conditions. Long-term safety and the clinical relevance of recent preclinical microbiome findings remain important areas for future investigation.

8 June 2026 in Journal of IMAB – Annual Proceeding (Scientific Papers)
Verified
Journal Article
Closed access
NKNikolinka Koleva
Nikolinka Koleva
Boris DinkovBoris Dinkov
Boris Dinkov
GSGalya Stavreva
Galya Stavreva
Mylin is a peptide hormone co-synthesized with insulin in pancreatic beta cells at a ratio of 1:100. Notably, amylin has a pronounced tendency to form toxic amyloid fibrils, a characteristic relevant to its pathological role. Purpose: This study aims to review both approved amylin analogs (AAs) and those currently in preclinical and clinical development, with a focus on their molecular structure, pharmacokinetics, receptor activity, and metabolic outcomes. Methods: A comprehensive literature review was conducted using PubMed and clinical trial databases. The analysis focused on structure-function relationships of AAs, biotechnological modifications influencing pharmacokinetics, receptor pharmacology (AMY 1-3), and their effects on glycemic control and appetite. Results: Pramlintide, approved by the FDA in 2005, delays gastric emptying, suppresses postprandial glucagon secretion, improves HbA1c, and induces modest weight loss. Dual amylin-calcitonin receptor agonists (DACRAs) represent next-generation drugs. Davalintide, in phase II trials, has demonstrated reductions in food intake, body weight, and HbA1c. It was ultimately discontinued due to insufficient efficacy and an unfavorable tolerability profile. KBP-089 and KBP-088 have shown favorable metabolic and hepatic effects in preclinical studies. Cagrilintide, a long-acting amylin analog combined with semaglutide (CagriSema), is currently in phase III clinical trials, showing significantly greater weight loss and improved glycemic control compared to monotherapy. Novel investigational agents, including NN1213, eloralintide, petrelintide, MET-233i, and amycretin, have demonstrated substantial weight loss, signaling a new era in amylin-based obesity pharmacotherapy. Conclusion: Amylin analogs present a compelling dual-targeted approach for managing T2D and obesity by improving both glycemic control and weight outcomes. Ongoing clinical trials will further define their long-term therapeutic role.